— often summarized as "what the drug does to the body" — is the study of a drug's biochemical and physiological effects. It focuses on the mechanisms of drug action, particularly the interactions between a drug and its molecular targets, which are most commonly proteins such as receptors, enzymes, ion channels, and transporters. The central tenet of PD is the concept of the drug-receptor interaction, where a drug (a ligand) binds to a target to produce a pharmacological response. Understanding the nuances of this interaction, such as affinity (the strength of binding) and efficacy (the ability to produce a response), is crucial for predicting a drug's effects and potential side effects.
Once a target is validated, high-throughput screening finds "hits" (molecules that bind to the target). But binding isn’t enough. Pharmacologists step in to define the relationship.
Using mathematical models to integrate PD, PK, and disease progression. is now accepted by the FDA. MIDD allows developers to simulate a Phase III trial using virtual patients, predicting optimal dosing for elderly, pediatric, or renally-impaired populations without exposing them to risk. pharmacology in drug discovery and development
Let me know what area of you would like to narrow down !
The graveyard of drug discovery is littered with drugs that cured cancer in mice but failed in humans. Why? — often summarized as "what the drug does
If PD is the "what," then pharmacokinetics is the "where, when, and how long." PK describes the movement of a drug into, through, and out of the body over time, answering: The PK journey is captured by four critical processes, summarized by the acronym ADME :
Understanding how the concentration of a drug correlates with the magnitude of the biological response. Understanding the nuances of this interaction, such as
: Bind to the receptor but do not activate it, effectively blocking endogenous signaling ligands from binding.